Asia Pacific Genital Herpes Treatment Market 2022-2032 by Virus Type (HSV-1, HSV-2), Drug Type (Acyclovir, Valacyclovir, Famciclovir, Others), Route of Administration (Oral, Topical, Injection), Patie...

Asia Pacific genital herpes treatment market will grow by 6.3% annually with a total addressable market cap of $10,932.1 million over 2023-2032, driven by the rising prevalence of sexually transmitted diseases, changing socio-cultural openness, increasing awareness about HSV infection and its sympto...

44985 | Genital Herpes Treatment

Europe Genital Herpes Treatment Market 2022-2032 by Virus Type (HSV-1, HSV-2), Drug Type (Acyclovir, Valacyclovir, Famciclovir, Others), Route of Administration (Oral, Topical, Injection), Patient Gen...

Europe genital herpes treatment market was valued at $958.5 million in 2022 and will grow by 4.1% annually over 2022-2032, driven by the rising prevalence of sexually transmitted diseases, changing socio-cultural openness, increasing awareness about HSV infection and its symptoms, improved access to...

44985 | Genital Herpes Treatment

North America Genital Herpes Treatment Market 2022-2032 by Virus Type (HSV-1, HSV-2), Drug Type (Acyclovir, Valacyclovir, Famciclovir, Others), Route of Administration (Oral, Topical, Injection), Pati...

North America genital herpes treatment market is projected to grow by 3.9% annually in the forecast period and reach $1,650.9 million by 2032, driven by the rising prevalence of sexually transmitted diseases, changing socio-cultural openness, increasing awareness about HSV infection and its symptoms...

44985 | Genital Herpes Treatment

Global Genital Herpes Treatment Market 2022-2032 by Virus Type (HSV-1, HSV-2), Drug Type (Acyclovir, Valacyclovir, Famciclovir, Others), Route of Administration (Oral, Topical, Injection), Patient Gen...

Global genital herpes treatment market will reach $5,051.8 million by 2032, growing by 4.7% annually over 2022-2032, driven by the rising prevalence of sexually transmitted diseases, changing socio-cultural openness, increasing awareness about HSV infection and its symptoms, improved access to antiv...

2023-03-09 | Genital Herpes Treatment

Asia Pacific genital herpes treatment market will grow by 6.3% annually with a total addressable market cap of $10,932.1 million over 2023-2032, driven by the rising prevalence of sexually transmitted diseases, changing socio-cultural openness, increasing awareness about HSV infection and its symptoms, improved access to antiviral medications, and the government supports. Highlighted with 32 tables and 44 figures, this 110-page report “Asia Pacific Genital Herpes Treatment Market 2022-2032 by Virus Type (HSV-1, HSV-2), Drug Type (Acyclovir, Valacyclovir, Famciclovir, Others), Route of Administration (Oral, Topical, Injection), Patient Gender (Female, Male), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies, Drug Stores), and Country: Trend Forecast and Growth Opportunity” is based on comprehensive research of the entire Asia Pacific genital herpes treatment market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2021-2022 and provides forecast from 2023 till 2032 with 2022 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify Asia Pacific genital herpes treatment market in every aspect of the classification from perspectives Virus, Drug Type, Route of Administration, Patient Gender, Distribution Channel, and Country. Based on Virus Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section. • HSV-1 • HSV-2 Based on Drug Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section. • Acyclovir • Valacyclovir • Famciclovir • Other Drugs By Route of Administration, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section. • Oral • Topical • Injection By Patient Gender, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section. • Female • Male By Distribution Channel, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section. • Retail Pharmacies • Hospital Pharmacies • Online Pharmacies • Drug Stores Geographically, the following national/local markets are fully investigated: • Japan • China • South Korea • Australia • India • Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines) For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2022-2032. The breakdown of national markets by Virus Type, Drug Type and Distribution Channel over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Selected Key Players: Abbott ADLEY FORMULATIONS Aurobindo Pharma Ltd. Avet Pharmaceuticals Inc. Bausch Health Companies Centurion Remedies Cipla Ltd. Eli Lilly & Company Finecure Pharmaceuticals GlaxoSmithKline Plc Glenmark Pharmaceuticals Macleods Pharmaceuticals Medico Remedies Merck & Co., Inc. Novartis AG Pfizer Reddy's Laboratories Sanofi SA Teva Pharmaceutical Industries Ltd. Torrent Pharma Viatris Inc. Zeelab Pharmacy Zydus Pharmaceuticals, Inc. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) ...

44985

Europe genital herpes treatment market was valued at $958.5 million in 2022 and will grow by 4.1% annually over 2022-2032, driven by the rising prevalence of sexually transmitted diseases, changing socio-cultural openness, increasing awareness about HSV infection and its symptoms, improved access to antiviral medications, and the government supports. Highlighted with 35 tables and 45 figures, this 111-page report “Europe Genital Herpes Treatment Market 2022-2032 by Virus Type (HSV-1, HSV-2), Drug Type (Acyclovir, Valacyclovir, Famciclovir, Others), Route of Administration (Oral, Topical, Injection), Patient Gender (Female, Male), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies, Drug Stores), and Country: Trend Forecast and Growth Opportunity” is based on comprehensive research of the entire Europe genital herpes treatment market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2021-2022 and provides forecast from 2023 till 2032 with 2022 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify Europe genital herpes treatment market in every aspect of the classification from perspectives Virus, Drug Type, Route of Administration, Patient Gender, Distribution Channel, and Country. Based on Virus Type, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section. • HSV-1 • HSV-2 Based on Drug Type, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section. • Acyclovir • Valacyclovir • Famciclovir • Other Drugs By Route of Administration, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section. • Oral • Topical • Injection By Patient Gender, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section. • Female • Male By Distribution Channel, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section. • Retail Pharmacies • Hospital Pharmacies • Online Pharmacies • Drug Stores Geographically, the following national/local markets are fully investigated: • Germany • UK • France • Spain • Italy • Netherlands • Rest of Europe (further segmented into Russia, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland) For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2022-2032. The breakdown of national markets by Virus Type, Drug Type and Distribution Channel over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Selected Key Players: Abbott ADLEY FORMULATIONS Aurobindo Pharma Ltd. Avet Pharmaceuticals Inc. Bausch Health Companies Centurion Remedies Cipla Ltd. Eli Lilly & Company Finecure Pharmaceuticals GlaxoSmithKline Plc Glenmark Pharmaceuticals Macleods Pharmaceuticals Medico Remedies Merck & Co., Inc. Novartis AG Pfizer Reddy's Laboratories Sanofi SA Teva Pharmaceutical Industries Ltd. Torrent Pharma Viatris Inc. Zeelab Pharmacy Zydus Pharmaceuticals, Inc. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) ...

44985

North America genital herpes treatment market is projected to grow by 3.9% annually in the forecast period and reach $1,650.9 million by 2032, driven by the rising prevalence of sexually transmitted diseases, changing socio-cultural openness, increasing awareness about HSV infection and its symptoms, improved access to antiviral medications, and the government supports. Highlighted with 25 tables and 44 figures, this 107-page report “North America Genital Herpes Treatment Market 2022-2032 by Virus Type (HSV-1, HSV-2), Drug Type (Acyclovir, Valacyclovir, Famciclovir, Others), Route of Administration (Oral, Topical, Injection), Patient Gender (Female, Male), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies, Drug Stores), and Country: Trend Forecast and Growth Opportunity” is based on comprehensive research of the entire North America genital herpes treatment market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2021-2022 and provides forecast from 2023 till 2032 with 2022 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify North America genital herpes treatment market in every aspect of the classification from perspectives Virus, Drug Type, Route of Administration, Patient Gender, Distribution Channel, and Country. Based on Virus Type, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section. • HSV-1 • HSV-2 Based on Drug Type, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section. • Acyclovir • Valacyclovir • Famciclovir • Other Drugs By Route of Administration, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section. • Oral • Topical • Injection By Patient Gender, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section. • Female • Male By Distribution Channel, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section. • Retail Pharmacies • Hospital Pharmacies • Online Pharmacies • Drug Stores Geographically, the following national/local markets are fully investigated: • U.S. • Canada • Mexico For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2022-2032. The breakdown of national markets by Virus Type, Drug Type and Distribution Channel over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Selected Key Players: Abbott ADLEY FORMULATIONS Aurobindo Pharma Ltd. Avet Pharmaceuticals Inc. Bausch Health Companies Centurion Remedies Cipla Ltd. Eli Lilly & Company Finecure Pharmaceuticals GlaxoSmithKline Plc Glenmark Pharmaceuticals Macleods Pharmaceuticals Medico Remedies Merck & Co., Inc. Novartis AG Pfizer Reddy's Laboratories Sanofi SA Teva Pharmaceutical Industries Ltd. Torrent Pharma Viatris Inc. Zeelab Pharmacy Zydus Pharmaceuticals, Inc. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) ...

44985

Global genital herpes treatment market will reach $5,051.8 million by 2032, growing by 4.7% annually over 2022-2032, driven by the rising prevalence of sexually transmitted diseases, changing socio-cultural openness, increasing awareness about HSV infection and its symptoms, improved access to antiviral medications, and the government supports. Highlighted with 84 tables and 80 figures, this 168-page report “Global Genital Herpes Treatment Market 2022-2032 by Virus Type (HSV-1, HSV-2), Drug Type (Acyclovir, Valacyclovir, Famciclovir, Others), Route of Administration (Oral, Topical, Injection), Patient Gender (Female, Male), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies, Drug Stores), and Region: Trend Forecast and Growth Opportunity” is based on comprehensive research of the entire global genital herpes treatment market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2020-2022 and provides forecast from 2023 till 2032 with 2022 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify global genital herpes treatment market in every aspect of the classification from perspectives Virus, Drug Type, Route of Administration, Patient Gender, Distribution Channel, and Region. Based on Virus Type, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section. • HSV-1 • HSV-2 Based on Drug Type, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section. • Acyclovir • Valacyclovir • Famciclovir • Other Drugs By Route of Administration, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section. • Oral • Topical • Injection By Patient Gender, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section. • Female • Male By Distribution Channel, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section. • Retail Pharmacies • Hospital Pharmacies • Online Pharmacies • Drug Stores Geographically, the following regions together with the listed national/local markets are fully investigated: • North America (U.S., Canada, and Mexico) • Europe (Germany, UK, France, Spain, Italy, Netherlands, Rest of Europe; Rest of Europe is further segmented into Russia, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland) • APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines) • South America (Brazil, Chile, Argentina, Rest of South America) • MEA (UAE，Saudi Arabia， South Africa and Rest of MEA) For each aforementioned region and country, detailed analysis and data for annual revenue ($ mn) are available for 2022-2032. The breakdown of all regional markets by country and split of each national market by Virus Type, Drug Type and Distribution Channel over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Selected Key Players: Abbott ADLEY FORMULATIONS Aurobindo Pharma Ltd. Avet Pharmaceuticals Inc. Bausch Health Companies Centurion Remedies Cipla Ltd. Eli Lilly & Company Finecure Pharmaceuticals GlaxoSmithKline Plc Glenmark Pharmaceuticals Macleods Pharmaceuticals Medico Remedies Merck & Co., Inc. Novartis AG Pfizer Reddy's Laboratories Sanofi SA Teva Pharmaceutical Industries Ltd. Torrent Pharma Viatris Inc. Zeelab Pharmacy Zydus Pharmaceuticals, Inc. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) ...

2023-03-09

LATEST REPORTS

PRESS RELEASES

Use Code

SDMR20

Purchase any report

AVAIL FLAT DISCOUNT